- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Pacira BioSciences is a drug manufacturers - specialty & generic business based in the US. Pacira BioSciences shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.13 – a decrease of 1.44% over the previous week. Pacira BioSciences employs 711 staff and has a trailing 12-month revenue of around $690.3 million.
What's in this guide?
Our top picks for where to buy Pacira BioSciences stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Pacira BioSciences stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PCRX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Pacira BioSciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Pacira BioSciences stock price (NASDAQ: PCRX)
Use our graph to track the performance of PCRX stocks over time.Pacira BioSciences shares at a glance
Information last updated 2024-10-24.
| Latest market close | $17.13 |
|---|---|
| 52-week range | $11.16 - $35.95 |
| 50-day moving average | $14.98 |
| 200-day moving average | $24.28 |
| Wall St. target price | $24.25 |
| PE ratio | 12.7015 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $1.34 |
Is it a good time to buy Pacira BioSciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pacira BioSciences price performance over time
Historical closes compared with the close of $17.13 from 2024-10-28
| 1 week (2024-10-23) | -1.44% |
|---|---|
| 1 month (2024-09-30) | 13.82% |
| 3 months (2024-07-30) | -12.33% |
| 6 months (2024-04-30) | -34.74% |
| 1 year (2023-10-30) | -38.34% |
|---|---|
| 2 years (2022-10-28) | -67.22% |
| 3 years (2021-10-29) | 52.28 |
| 5 years (2019-10-30) | 40.7 |
Is Pacira BioSciences stock undervalued or overvalued?
Valuing Pacira BioSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira BioSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pacira BioSciences's P/E ratio
Pacira BioSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Pacira BioSciences shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Pacira BioSciences's EBITDA
Pacira BioSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $175.3 million.
The EBITDA is a measure of a Pacira BioSciences's overall financial performance and is widely used to measure a its profitability.
Pacira BioSciences financials
| Revenue TTM | $690.3 million |
|---|---|
| Operating margin TTM | 17.4% |
| Gross profit TTM | $393.2 million |
| Return on assets TTM | 3.96% |
| Return on equity TTM | 7.54% |
| Profit margin | 9.21% |
| Book value | $19.07 |
| Market Capitalization | $785.1 million |
TTM: trailing 12 months
Pacira BioSciences share dividends
We're not expecting Pacira BioSciences to pay a dividend over the next 12 months.
Pacira BioSciences share price volatility
Over the last 12 months, Pacira BioSciences's shares have ranged in value from as little as $11.164 up to $35.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira BioSciences's is 0.839. This would suggest that Pacira BioSciences's shares are less volatile than average (for this exchange).
Pacira BioSciences overview
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc.
Frequently asked questions
What percentage of Pacira BioSciences is owned by insiders or institutions?Currently 2.029% of Pacira BioSciences shares are held by insiders and 117.23% by institutions. How many people work for Pacira BioSciences?
Latest data suggests 711 work at Pacira BioSciences. When does the fiscal year end for Pacira BioSciences?
Pacira BioSciences's fiscal year ends in December. Where is Pacira BioSciences based?
Pacira BioSciences's address is: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 What is Pacira BioSciences's ISIN number?
Pacira BioSciences's international securities identification number is: US6951271005 What is Pacira BioSciences's CUSIP number?
Pacira BioSciences's Committee on Uniform Securities Identification Procedures number is: 695127100
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question